Lipotec introduced two peptides at in-cosmetics Asia which innovatively target sensitive skin. Delisens focuses on attenuating the feelings of discomfort in sensitive skin, such as itching, whereas Telangyn offers efficacy in improving facial redness, such as rosacea.
Acute or chronic skin inflammation lowers the threshold for pruritic stimuli which is the origin of the itch sensation. Moreover, it increases the transepidermal water loss, pH and redness while, reducing protection against irritant factors. This leads to a fragile appearance, premature wrinkle formation, erythema among others macroscopic effects which characterise sensitive skin.
Delisens attenuates neurogenic inflammation and relieves itching by inhibiting Proteinase-Activated Receptor 2 (PAR-2)-induced release of pro-inflammatory mediators, which is fundamental to the processing of pruritic or/ad inflammatory signals. Skin exposure to allergens or UV radiation leads to exacerbated inflammation and amplified pain and itch sensation. Delisens proved its efficacy in vitro in reducing the release of inflammatory cytokines, induced by cosmetic allergens, by 58.2% after applying a cream with 4% Delisens Solution. Moreover it protects the human dermal fibroblasts against UV radiation and stimulates the proliferation of human keratinocyte, contributing to the restoring of the barrier function and the integrity of skin tissue. Sensitive dry skin will also benefit from enhanced skin moisturising in formulations containing this hexapeptide which increased hydration of the legs by 34% compared to placebo after only a week of treatment applying a cream containing 2% Delisens™ Solution. As showed in vivo, it ameliorated skin dryness, scaling while improving smoothness, softness and suppleness.
Erythema, itching or inflammation of capillaries, among others, are disorders associated with skin redness and are a concern for millions of people, especially for pale-skinned women over 30. Rosacea, characterised by prolonged redness and dilated capillaire, is said to affect 45 million of people worldwide (Mintel, 2012). Telangyn improves facial redness by diminishing LL-37-induced release of interleukins (IL)-6 and IL-8. An exaggerated inflammatory response can also damage the dermal connective tissue since it increases the proteolytic degradation of the extracellular matrix (ECM) by activating Matrix Metalloproteinases. Telangyn has proved in vitro to have a significant anti-collagenase activity, thus helping to improve skin firmness and elasticity by decreasing the degradation of collagen, while providing photoprotection to cells. It ameliorates the extent of erythema, redness and skin roughness in volunteers with mild rosacea. At the end of a 4-week treatment applying a cream containing 2% Telangyn Solution, the dermatological evaluation showed its efficacy in decreasing erythematic intensity by 19.2%, skin redness by 17.7%, extent by 17.9% and skin roughness by 7.5%.
Telangyn’s anti-tyrosinase activity and capacity to reduce melanin content increases the evenness of the skin tone, diminishing the hyperpigmentation and improving the dull appearance of the skin.
Both active ingredients are part of Aimtec, Lipotec’s brand for peptides and organic molecules, and are designed with sensitive skin in mind.
